ArticleInternational journal of clinical and experimental medicine2015
Tissue engineered skin for diabetic foot ulcers: a meta-analysis.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 8 citations in OpenAlex.
- Restoring vasculogenic potential of endothelial cells from diabetic patients through spheroid formation.Cellular and molecular bioengineering · 2018Article
- The association between MCP-1, VEGF polymorphisms and their serum levels in patients with diabetic foot ulcer.Medicine · 2018Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the effectiveness of tissue engineered skin in the management of diabetic foot ulcer. We searched PubMed, EMBASE and ISI Web of Science database in order to obtain the randomized controlled trial with interventions of tissue engineered skin. A meta-analysis was used to compare the effectiveness between tissue engineered skin and conventional treatment in the patients with diabetic foot ulcer. This meta-analysis was performed by STATA 11 software. The risk factor was analyzed by random effect model pooled odds ratio (OR) and 95% confidence interval (CI). Moreover, the funnel plot was used to assess the published bias of articles. Eight studies were included, and a total of 1060 cases were involved for this meta-analysis. The OR of tissue engineered skin for diabetic foot ulcers was 1.76 (95% CI: 1.35-2.30). A subgroup analysis was conducted for different types of tissue engineering skin, combined OR was 1.91 (95% CI: 1.12-3.27) for Derma graft, 2.05 (95% CI: 1.20-3.50) for Graft skin and 1.57 (95% CI: 0.91-2.70) for Hyalo graft 3D. Applying tissue engineered skin is more effective in the improvement of wound closure in patients with diabetic foot ulcers, compared with conventional treatment.
Indexed as
Identifiers
26770419PMC4694319W2418104732What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.